A New Approach for Cardiovascular Disease (Dr. Matthew O’Connor, Cyclarity Therapeutics)

<p>In today’s episode, Chris is joined by Dr. Matthew "Oki" O'Connor, CEO for Scientific Affairs at Cyclarity Therapeutics, a company focused on eliminating arterial plaque, a prevalent issue in old age. Dr. O'Connor shares his insights on the causes and effects of atherosclerosis, the leading cause of death worldwide, and how aging contributes to plaque build-up. The podcast emphasizes the need for a paradigm shift in addressing cardiovascular disease and highlights the importance of new approaches to repair vessels throughout the body and brain.</p><p>Together, Chris and Dr. O’Connor begin by discussing atherosclerosis, its significant impact on cardiovascular disease, and the need to understand the molecular and biochemical mechanisms underlying aging and diseases related to aging. They also cover the limitations of current clinical treatments for atherosclerosis and the importance of a paradigm shift towards new approaches that can repair vessels throughout the body and brain. Dr. O’Connor then goes on to describe Cyclarity’s unique drug, a cyclodextrin, explaining how it could be a promising solution to the harmful effects of atherosclerosis. The podcast also explores the potential of combination therapy with traditional lipid-lowering drugs to address multiple aspects of atherosclerosis.</p><p>Join Chris and Dr. O’Connor here today to gain a greater understanding of the remarkable work undertaken by Cyclarity Therapeutics, the impact of aging on cardiovascular health, the need for new approaches to address atherosclerosis, and the unique drug therapy combination that may offer a promising solution, revolutionizing its treatment in the process.</p><p><strong>The Finer Details:</strong></p><ul><li>Cyclarity Therapeutics and the work they undertake&nbsp;</li><li>Atherosclerosis&nbsp;</li><li>Cardiovascular dysfunction</li><li>The build-up of arterial plaque</li><li>The implications of aging-related targets</li><li>The need for a paradigm shift towards looking at new approaches to repair vessels&nbsp;</li><li>T